FDA: Breakthrough Therapy Designation for LOXO-292, a selective RET inhibitor
The FDA ( U.S. Food and Drug Administration ) has granted Breakthrough Therapy Designation to LOXO-292, a selective RET inhibitor, for: the treatment of patients with metastatic RET-fusion-positive no ...
read article